Dublin, Nov. 09, 2017 (GLOBE NEWSWIRE) -- The "From R&D Investment to Externalization: Where is the Pharma Industry Maximizing Value?" report has been added to Research and Markets' offering.

Pharmaceutical companies are attempting to maximize value from all angles, including internal investment in R&D and externalization via deal-making. The growth in these two models has had an impact on both revenue derived from internally developed products, as well as externalized drugs.

Key Topics Covered:

1 EXECUTIVE SUMMARY

2 OVERALL TRENDS

3 R&D INVESTMENT TRENDS

• Overall R&D Investment trends
• Peer set R&D investment trends
• R&D productivity
• Bibliography

4 BIG PHARMA LICENSING TRENDS

• Alliance volume and value
• In-licensing and out-licensing
• Phase trends
• Therapy area trends
• Bibliography

5 REVENUE EXTERNALIZATION TRENDS

• Higher volume of unpartnered drugs, but partnered candidates are growing faster
• Externalized revenue growth due to M&A, co-developed drugs, and acquired products
• Peer set externalized revenue trends
• Higher average per-drug revenue expected for externalized products
• Bibliography

6 APPENDIX

• Scope
• Methodology
  

For more information about this report visit https://www.researchandmarkets.com/research/f39gpt/from_randd

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Pharmaceuticals

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.